MediWound Ltd. (MDWD)
NASDAQ: MDWD · IEX Real-Time Price · USD
1.86
+0.07 (3.91%)
Jul 5, 2022 3:59 PM EDT - Market closed
Company Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration.
It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.
MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd.
| Country | Israel |
| Founded | 2000 |
| IPO Date | Mar 20, 2014 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Employees | 77 |
| CEO | Sharon Malka |
Contact Details
Address:
42 Hayarkon Street Yavne 8122745 Israel | |
| Phone | 972 7 797 14100 |
| Website | mediwound.com |
Stock Details
| Ticker Symbol | MDWD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0001593984 |
| CUSIP Number | M68830104 |
| ISIN Number | IL0011316309 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Prof. Lior Rosenberg M.D. | Co-Founder and Chief Medical Technology Officer |
| Boaz Gur-Lavie CPA, M.B.A. | Chief Financial Officer |
| Yaron Meyer Adv. | Executive Vice President, General Counsel and Corporate Secretary |
| Dr. Ety Klinger | Chief Research & Development Officer |
| Stephen T. Wills CPA, CPA, MST | Executive Chairman |
| Ofer Gonen B.Sc. | Chief Executive Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 9, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Jun 6, 2022 | EFFECT | Notice of Effectiveness |
| May 25, 2022 | F-3 | Registration statement by foreign private issuers |
| May 17, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 17, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 12, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Mar 22, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Mar 17, 2022 | SC 13D | General statement of acquisition of beneficial ownership |
| Mar 17, 2022 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] |
| Mar 17, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |